Acadia Pharmaceuticals Inc. company information, Employees & Contact Information

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 Business Wire

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders® Yahoo Finance

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Stock Titan

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 Business Wire

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer Yahoo Finance

JPM25: After taking the wheel at Acadia, CEO Catherine Owen Adams looks to steer firm toward $1B in sales Fierce Pharma

161,676 Stock Options at $25.50: Acadia Pharmaceuticals Issues Major Inducement Grants to New Hires Stock Titan

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent Yahoo Finance

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers Business Wire

Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study statnews.com

Biotech Stocks Diverge As Genetic Disease Drug Fails Investor's Business Daily

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish (ACAD) Seeking Alpha

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer Yahoo Finance

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 Investor's Business Daily

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint Yahoo Finance

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million Business Wire

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study Yahoo Finance

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 Yahoo Finance

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview Yahoo Finance

Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions BioSpace

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M MedCity News

(trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older Business Wire

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology Yahoo Finance

ACADIA Pharmaceuticals: Advancing On Several Fronts (NASDAQ:ACAD) Seeking Alpha

Acadia Pharmaceuticals: Reeling After PWS Failure - Downgrading To Hold (NASDAQ:ACAD) Seeking Alpha

How 'Growing Pains' Affected Not Just One — But Three — Biotechs Investor's Business Daily

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short Benzinga

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis Business Wire

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview (NASDAQ:ACAD) Seeking Alpha

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases Business Wire

Acadia to make $100M profit from selling pediatric review voucher for $150M Fierce Biotech

ACADIA Pharmaceuticals Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2025-08-07 Seeking Alpha

Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study ScienceDirect.com

FDA Approves Acadia's Trofinetide for Rett Syndrome NeurologyLive

Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study Nature

Acadia’s Mark Schneyer to Serve as Interim Chief Financial Officer citybiz

Ryan Reynolds Announces More to Parkinson’s® Campaign Business Wire

ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development Business Wire

FDA Advisory Committee Votes Down Pimavanserin's Efficacy in AD Psychosis Ahead of PDUFA NeurologyLive

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome Business Wire

FDA Issues Second CRL for Pimavanserin, Now for the Treatment of Alzheimer Disease Psychosis NeurologyLive

Acadia Addresses Concerns Over Nuplazid Safety in Parkinson’s Disease Patients Medical Professionals Reference

Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer’s disease Wiley Online Library

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis MarketBeat